Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

BACKGROUND AND OBJECTIVES: The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR‐SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT‐P13 was not inferior to continued treatment with infliximab originator. The NOR‐SWITCH extension...

Descripción completa

Detalles Bibliográficos
Autores principales: Goll, G. L., Jørgensen, K. K., Sexton, J., Olsen, I. C., Bolstad, N., Haavardsholm, E. A., Lundin, K. E. A., Tveit, K. S., Lorentzen, M., Berset, I. P., Fevang, B. T. S., Kalstad, S., Ryggen, K., Warren, D. J., Klaasen, R. A., Asak, Ø., Baigh, S., Blomgren, I. M., Brenna, Ø., Bruun, T. J., Dvergsnes, K., Frigstad, S. O., Hansen, I. M., Hatten, I. S. H., Huppertz‐Hauss, G., Henriksen, M., Hoie, S. S., Krogh, J., Midtgard, I. P., Mielnik, P., Moum, B., Noraberg, G., Poyan, A., Prestegård, U., Rashid, H. U., Strand, E. K., Skjetne, K., Seeberg, K. A., Torp, R., Ystrøm, C. M., Vold, C., Zettel, C. C., Waksvik, K., Gulbrandsen, B., Hagfors, J., Mørk, C., Jahnsen, J., Kvien, T. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850326/
https://www.ncbi.nlm.nih.gov/pubmed/30762274
http://dx.doi.org/10.1111/joim.12880

Ejemplares similares

Ejemplares similares